A Critical Week for Bayer: Financial Report and Legal Deadlines Converge

Bayer's 2025 report to detail Roundup litigation costs as a key $7.25B settlement faces delays and the Supreme Court prepares a pivotal review.

Investors in Bayer are facing a pivotal week, with two major events highlighting the ongoing pressure from the company's legal challenges. The chemical and pharmaceutical giant's shares have reflected this tension, declining by 2.97% to €40.51 in recent trading and posting a 9.09% loss over the past month.

Annual Report to Reveal Litigation's Financial Toll

The immediate focus is the publication of Bayer's 2025 Annual Report, scheduled for 7:30 AM CET on Wednesday, March 4, 2026. This financial disclosure arrives at a delicate moment, as the sprawling Roundup litigation continues to dictate the group's fiscal planning.

Key figures are expected to underscore the burden. The company has already increased its provisions for legal disputes to €11.8 billion. Furthermore, management has forecast a likely negative free cash flow for 2026, driven significantly by anticipated litigation-related payments of approximately €5 billion in that year alone.

To manage these substantial outflows, Bayer has secured bridge financing of $8 billion. The subsequent strategy involves refinancing this debt through senior unsecured bonds and hybrid securities. For shareholders, this underscores that liquidity and financing costs will remain central concerns throughout the coming year.

Stalled Settlement Casts Uncertainty

Simultaneously, a major proposed legal resolution faces delays. A $7.25 billion settlement aimed at resolving a significant portion of the Roundup lawsuits has hit an obstacle. Judge Timothy Boyer of the St. Louis City Circuit Court, who is overseeing the class action, has yet to schedule a hearing for preliminary approval.

Complicating matters, plaintiff attorneys have voiced organized resistance. In a filing made public on Wednesday, several law firms argued against rushing the settlement for provisional approval on March 4—a date that falls just 15 days after the deal's announcement. This date was initially intended for plaintiffs to signal their preliminary support or rejection. Multiple lawyers are now requesting more time to review the proposal with their clients.

This represents the first major coordinated pushback against Bayer's effort to settle roughly 65,000 pending Roundup claims in federal and state courts. Bayer maintains confidence that the settlement "is fair to all claimants and deserves court approval." The negotiating plaintiff attorneys, for their part, have stated they hope for no delay in the preliminary approval hearing.

Supreme Court Review Looms as Potential Game-Changer

Running in parallel is another potentially decisive legal thread. The U.S. Supreme Court has agreed to review whether federal pesticide law preempts state-level failure-to-warn claims against Bayer. Oral arguments are set for late April 2026.

The company views this case as fundamental to limiting its liability within the Roundup litigation complex. A ruling is expected by the summer of 2026, and its outcome could materially alter the negotiating dynamics in any settlement discussions.

Wednesday, March 4, thus becomes a confluence of critical timelines: the 7:30 AM release of the annual report and a related investor video call on FY/Q4 2025 will provide a financial snapshot, while the $7.25 billion settlement's schedule remains in flux and the late April Supreme Court date stands as the next fixed milestone in the ongoing legal saga.